Enhancing CLIA Act of 2026
Introduced May 19, 2026 · Last action May 19, 2026
Plain English Summary
This bill reshapes regulation of laboratory-developed tests (LDTs)—diagnostic tests created and performed within single hospital or clinical laboratories—by removing FDA oversight and placing it under CLIA (Clinical Laboratory Improvement Amendments) instead. Labs must document that their tests have analytical and clinical validity, but can do so through internal evidence, peer-reviewed literature, or optional third-party review rather than FDA approval. Labs must register their tests in a central database and report serious errors.
Who benefits
Clinical laboratory companies and hospital in-house laboratories that develop and perform their own diagnostic tests (especially large health systems with multiple labs under common ownership); academic medical centers with high-complexity lab certifications; the 'Big Three' lab companies (LabCorp, Quest Diagnostics) that operate affiliated networks under common ownership; public health agencies and CDC-coordinated laboratory networks; laboratory-developed test developers who avoid FDA premarket approval timelines and costs; genetic testing labs, cancer genomics labs, and specialty diagnostics labs operating within single corporate entities.
Who pays / loses
Patients who receive tests without FDA validation pathway (though testing remains regulated by CLIA); IVD device manufacturers whose lawfully-marketed tests compete with unregulated LDT modifications; diagnostic companies that commercialize tests across multiple independent labs (they remain under FDA regulation if distributed commercially); competitors of large health systems that cannot perform in-house testing; healthcare providers who must rely on lab self-certification of test validity rather than FDA clearance; payers (Medicare, commercial insurers, employers) who may cover unvalidated or low-validity tests; regulators with reduced authority to oversee test accuracy at point of use.
Funding & Lobbying Interests
The sponsor (Rep. Dunn, R-FL) received minimal healthcare industry donations ($4,100 in 2024), but the bill's beneficiaries are major clinical laboratory networks, hospital systems, and specialty genomics labs that lobby for reduced FDA oversight. LabCorp and Quest Diagnostics—the two largest U.S. clinical labs—have historically opposed FDA regulation of LDTs and would benefit from regulatory streamlining. Academic medical centers and large health systems with in-house labs are active in professional associations (AACC, CAP) advocating for this approach. The bill also benefits genetic testing companies (Myriad, Invitae, etc.) that operate proprietary lab networks and prefer CLIA-only regulation. Device manufacturers (Illumina, Roche, Siemens) benefit from loosened restrictions on modification of their devices for LDT use.
Political Impact
Affected Groups
Approximately 260,000+ U.S. clinical laboratories subject to CLIA; patients undergoing diagnostic testing (estimated ~7 billion tests annually in the U.S.); academic medical centers and large health systems (estimated ~6,000+ hospitals); specialty genetics and oncology testing labs; genetic counseling and cancer care practices; Medicare and Medicaid beneficiaries (as payers); commercial health insurers; state health departments (some, like New York, currently regulate LDTs independently); international laboratories wanting FDA-backed quality assurance.
Political Subtext
Proponents argue this bill reduces regulatory burden on laboratories, speeds innovation in diagnostic testing (especially in genomics, digital pathology, and next-generation sequencing), and acknowledges that CLIA-certified labs can self-validate tests without FDA approval delays—a position held by the American Association for Clinical Chemistry, the College of American Pathologists, and large academic laboratories. They note LDTs represent ~50% of clinical tests and that current FDA authority over LDTs is unclear and inconsistently enforced. Critics contend the bill weakens patient safety by removing independent FDA scrutiny, creating a two-tier system where FDA-approved tests face rigorous validation but LDTs need only internal or third-party validation. Critics worry optional third-party review will be gamed by industry-friendly accreditors, and that the centralized database lacks enforcement teeth because the Secretary must have 'credible and verifiable information' to challenge a test. The bill assumes CLIA oversight and laboratory self-governance are sufficient; non-partisan evidence (GAO reports, prior FDA oversight initiatives) documents inconsistent CLIA compliance and quality across labs, particularly in smaller facilities. The bill also de facto allows FDA's authority to be weakened by permitting already-approved/cleared tests to escape future FDA oversight if labs reclassify them as LDTs.
Real-World Stakes
If passed, patients will immediately receive diagnostic results from thousands of tests no longer subject to FDA review. This mirrors the regulatory landscape prior to 2014, when FDA warned of oversight gaps for LDTs but lacked clear authority. New York State's precedent (New York Clinical Laboratory Evaluation Program) shows state-level oversight can catch validity problems, but is resource-intensive and covers only NY labs. The 2015 FDA-CLIA joint oversight effort largely stalled due to lack of congressional authority. Studies of genomic LDTs (PLoS Medicine, 2015, 2017) found significant variation in clinical validity claims, false positives in cancer risk assessment, and inadequate disclosure of limitations. The bill's optional third-party review mirrors accreditation models (CAP, CLIA certificates of compliance) where inspections occur every 2 years—creating gaps for test validity drift. The centralized database is transparent but non-binding: labs may report tests, but the Secretary's authority to halt false or invalid tests is narrow (requires 'credible and verifiable information,' then multi-step appeal, then 45+30+45 day reviews). Comparable precedent: the FDA's MolDX program (referenced in the bill as a deemed-affirmation pathway for Medicare coverage) has faced criticism for approving tests with thin evidence, then slow enforcement; revocation of MolDX approval typically takes 1–2 years. For companion diagnostics (tests tied to drug approval), the bill allows LDT use without separate FDA validation, which could accelerate access but also risks approving drugs with unvalidated or inconsistent diagnostic partners.
Sponsor
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
Top contributing industries
Other$131,170
Finance$17,286
Law$7,600
Healthcare$4,100
Construction$2,850
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.